Long-term outcome analysis of reduced-intensity ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
Auteur(s) :
Robinson, Stephen [Auteur]
Boumendil, Ariane [Auteur]
Finel, Herve [Auteur]
Peggs Karl, S [Auteur]
Chevallier, Patrice [Auteur]
Sierra, Jorge [Auteur]
Finke, Jurgen [Auteur]
Poire, Xavier [Auteur]
Maillard, Natacha [Auteur]
Milpied, Noel [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Koh, Mickey [Auteur]
Kroger, Nicolaus [Auteur]
Nagler, Arnon [Auteur]
Koc, Yener [Auteur]
Dietrich, Sascha [Auteur]
Montoto, Silvia [Auteur]
Dreger, Peter [Auteur]
Boumendil, Ariane [Auteur]
Finel, Herve [Auteur]
Peggs Karl, S [Auteur]
Chevallier, Patrice [Auteur]
Sierra, Jorge [Auteur]
Finke, Jurgen [Auteur]
Poire, Xavier [Auteur]
Maillard, Natacha [Auteur]
Milpied, Noel [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Koh, Mickey [Auteur]
Kroger, Nicolaus [Auteur]
Nagler, Arnon [Auteur]
Koc, Yener [Auteur]
Dietrich, Sascha [Auteur]
Montoto, Silvia [Auteur]
Dreger, Peter [Auteur]
Titre de la revue :
Bone Marrow Transplantation
Nom court de la revue :
Bone Marrow Transplant.
Numéro :
53
Pagination :
617–624
Date de publication :
2018-05
ISSN :
1476-5365
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential ...
Lire la suite >Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.Lire moins >
Lire la suite >Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with mantle cell lymphoma who relapse after an autoSCT. However, the long-term efficacy of RIST and its curative potential have not been clearly demonstrated. We studied the long-term outcome of patients receiving a RIST for MCL as reported to the EBMT. A total of 324 patients, median age 57 years (range 31-70), underwent a RIST between 2000 and 2008; 43% of the patients had received >3 lines of prior therapy, including an autoSCT in 46%. Non-relapse mortality (NRM) was 10% at 100 days and 24% at 1 year and was lower for patients receiving anti-thymocyte globulin (ATG)/ALG (RR 0.59, p = 0.046). After a median follow-up of 72 months (range 3-159), 118 patients relapsed at a median of 8 months post RIST (range 1-117). The cumulative incidence of relapse was 25% and 40% at 1 and 5 years, respectively, and was associated with chemorefractory disease (HR 0.49, p = 0.01) and the use of CAMPATH (HR 2.59, p = 0.0002). The 4-year progression-free survival rate and overall survival rate was 31 and 40%, respectively. RIST results in long-term disease-free survival in about 30% of the patients, including those patients relapsing after a prior autoSCT.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Date de dépôt :
2019-03-01T14:17:59Z
2024-01-30T13:44:52Z
2024-01-30T13:44:52Z